Data / Federal rules / 2026-10898
Medical Devices; Hematology and Pathology Devices; Classification of the Von Willebrand Factor Assay
The Food and Drug Administration published this final rule in the Federal Register on June 1, 2026. It took effect on June 1, 2026.
SpecStream is the live web data engine for teams and agents. It reads every rule and proposed rule in the Federal Register each morning, and this page is that reading. Name your industry once and new rules, comment deadlines and effective dates arrive in your sheet, CRM, Slack or agent as they are published.
What the agency says
The Food and Drug Administration (FDA) is classifying the von Willebrand factor assay into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the von Willebrand factor assay. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.
Key facts
- Document number
- 2026-10898
- Type
- Final rule
- Action
- Final amendment; final order
- Agency
- Health and Human Services Department; Food and Drug Administration
- Published
- June 1, 2026
- Takes effect
- June 1, 2026
- Dates
- This order is effective June 1, 2026. The classification was applicable on September 29, 2022.
- Docket
- Docket No. FDA-2026-N-5725
- Code of Federal Regulations
- 21 CFR 864
- Topics
- Blood; Medical devices; Packaging and containers
- Pages
- 3
Other documents from the Food and Drug Administration
Everything from the Food and Drug Administration · Rules on blood · Rules on medical devices · Rules on packaging and containers · Published in June 2026
Read from the Federal Register API, last updated 2026-10-23. The document on federalregister.gov is the official record; dates and dockets can change through later corrections. Free to reuse with credit to SpecStream under CC BY 4.0.